Moderna reports positive results for RSV vaccine

Moderna's vaccine was found to be nearly 84 percent effective against RSV-linked diseases in Phase III trials -- the final stage of human testing -- the firm said in a statement.

PREMIUM Health

The positive results come after Pfizer announced in December that its own RSV vaccine for over-60s was granted priority review status by the US Food and Drug Administration./AFP

By NewVision Reporter

Journalists @NewVision

#Moderna #respiratory syncytial virus (RSV)

US biotech company Moderna on Tuesday announced positive interim trial results for its vaccine against respiratory syncytial virus (RSV) in adults over the age of 60.

There are no jabs currently

Global COVID cases up 80% as new subvariant rises

Health

U.S. FDA approves updated COVID-19 vaccines against currently circulating variants

Health

Moderna reports positive results for RSV vaccine

Moderna's vaccine was found to be nearly 84 percent effective against RSV-linked diseases in Phase III trials -- the final stage of human testing -- the firm said in a statement.

The positive results come after Pfizer announced in December that its own RSV vaccine for over-60s was granted priority review status by the US Food and Drug Administration./AFP

By NewVision Reporter

Journalists @NewVision

Related Stories

Global COVID cases up 80% as new subvariant rises

U.S. FDA approves updated COVID-19 vaccines against currently circulating variants

Moderna rebuked over plan to hike COVID vaccine to $130

Amid low demand, experts persuade Ugandans to vaccinate against COVID-19

Moderna says updated Covid vaccine fares well against new variant

Pfizer and BioNTech COVID vaccine broke patent — German court